Skip to content
AnalystLens
Back to EXELBalance Sheet

Exelixis Long-Term Debt 2011-2018 | EXEL

quarterly through Q4 FY2018

Latest quarter · Q4 FY2018

$0

Source: 10-QQ4 FY2018

By quarter▲▼ vs a year before
Fiscal yearQ1Q2Q3Q4
FY18$113M−70.8%$0−100.0%$0−100.0%$0−100.0%
FY17$389M+6.7%$396M+6.7%$191M−49.4%$189M−54.7%
FY16$364M+6.7%$371M+46.3%$377M+46.3%$418M+61.3%
FY15$342M+7.4%$254M−21.6%$258M−21.7%$259M−22.8%
FY14$318M+276.5%$324M+286.7%$329M+297.5%$335M+4.0%

Shaded by size: darkest is the largest quarter shown; ringed is the latest reported; a dash marks a quarter with no separate figure. Each quarter sits by its period-end date.

Long-Term Debt History

Quarterly data from 10-Q and 10-K reports

  1. $0
QoQ changeLargest recent move−51.8%in Q3 FY17

2 older moves run past ±100% (largest +289.2%); point at, tap or drag across the bars to read one.

Long-Term Debt, period by period

PeriodValueSource
Q4FY2018$0—10-K
Q3FY2018$0—10-Q
Q2FY2018$0−100.0%10-Q
Q1FY2018$113.3M−40.1%10-Q
Q4FY2017$189.1M−0.9%10-K
Q3FY2017$190.9M−51.8%10-Q
Q2FY2017$396.1M+1.9%10-Q
Q1FY2017$388.7M−7.0%10-Q
Q4FY2016$417.9M+10.7%10-K
Q3FY2016$377.4M+1.7%10-Q
Q2FY2016$371.2M+1.9%10-Q
Q1FY2016$364.4M+40.6%10-Q
Q4FY2015$259.1M+0.5%10-K
Q3FY2015$258.0M+1.7%10-Q
Q2FY2015$253.7M−25.7%10-Q
Q1FY2015$341.6M+1.8%10-Q
Q4FY2014$335.5M+1.8%10-K
Q3FY2014$329.5M+1.8%10-Q
Q2FY2014$323.6M+1.8%10-Q
Q1FY2014$318.0M−1.4%10-Q
Q4FY2013$322.6M+289.2%10-K
Q3FY2013$82.9M−0.9%10-Q
Q2FY2013$83.7M−0.9%10-Q
Q1FY2013$84.5M−52.2%10-Q
Q4FY2012$176.6M+105.9%10-K
Q3FY2012$85.8M−0.9%10-Q
Q2FY2012$86.6M−49.3%10-Q
Q4FY2011$170.7M—10-K
Company
Exelixis
Ticker
EXEL
Sector
Healthcare
Industry
Biological Products, (No Diagnostic Substances)